Cure Rare Disease has finished developing the infrastructure necessary to enable continuous development of precision medicine therapeutics for genetic diseases
- We have onboarded two critical partners to enable continuous development: Charles River Labs and Nationwide Children’s Hospital.
- Charles River will lead regulatory engagement and GLP toxicology studies both of which are critical to reaching patient dosing.
- Nationwide Children’s Hospital will produce research and clinical grade AAV (viral vector) for systemically delivering the therapeutic to patients.
Our first patient is expected to be diagnosed in 2020 while we have recently enrolled (3) additional DMD patients into the precision medicine process.
We need the communities help to increase our capacity to treat more patients with customized therapeutics.
Find out how you can help support us: https://cureraredisease.org/help-fund-treatments/
- We have engaged FDA to begin regulatory conversations ultimately leading into clinical trial.
The purpose of Cure Rare Disease is to end rare disease. There are over 7,000 different rare diseases impacting over 300 million people worldwide.
Drug development for rare disease is challenging. The “one size fits all” approach to drug development is not sufficient.
In 2018, the world saw one of the first examples of the power of personalized medicine to save those with complex genetic diseases for which there are no treatments.
Cure Rare Disease has formed a collaboration with the leading researchers to develop a customized therapeutics platform, in time to save our loved ones.
The approach that Cure Rare Disease is pursuing is unprecedented. By aligning researchers around a clear goal with foundation support and oversight promotes accountability, takes advantage of group wisdom to enable rapid development without traditional drawbacks.
Collaboration among our researchers enables faster innovation.
Our collaboration brings together researchers and clinicians who are luminaries and pioneers.
Moreover, Cure Rare Disease has the support of leaders in the space who are pioneers in developing customized treatments.
THE STRATEGY TO END DUCHENNE
Our strategy is to create a common foundation from which our collaborators can take multiple therapeutic “shots on goal”.
The process is 4-fold and begins with establishing a cell line unique to the individual. With this, we can better analyze the genetic mutations and, downstream, test therapeutic candidates for efficacy against the individual’s cells.
The analytical phase guides the subsequent stages of therapeutic development. Our team will use computational prediction to guide which of the therapeutic “tools” will be most effective at restoring functional protein levels based on the individual’s genetics.
Of the therapeutic candidates, the lead candidate will be developed and optimized. Once complete, we will move into a single (or small scale) clinical trial.
Our goal is to be in clinical trial in 1-2 years.
In parallel, we will begin to generalize the process by creating cohorts of different mutation groups and include other individuals.